Healthcare
Sutro Biopharma, Inc.(STRO)
Live Price
Offline$29.63
+4.29% today
1Y Change
+264.92%
Window
Jun 20, 2025 โ May 29, 2026
- Market Cap
- $300.00M
- Revenue Growth
- +65.2%
- EPS Growth
- +24.0%
- Dividend Yield
- 0.0%
Coverage: 237 bars ยท Jun 20, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sutro Biopharma, Inc. (STRO) is a Healthcare stock with a market cap of $300.00M and listed on NASDAQ. The stock last traded around $29.63 and up 264.9% across the available one-year price window (Jun 20, 2025 โ May 29, 2026). Baseline metrics include revenue growth of +65.2%, EPS growth of +24.0%, a dividend yield of 0.0%. What stands out right now is revenue +65.2%, EPS +24.0%, free cash flow +8.1% with operating margin -150.2% and ROIC -144.5%. Valuation is more restrained than many high-expectation growth names at price/sales 3.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines STRO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+65.2% vs +7.6% peer median
Operating Margin
Below sector median
-150.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +65.2% and EPS at +24.0%, with operating margin around -150.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +1.4% | -20.3% | โ |
2026 Mar 26, 2026 | -13.5% | -1.9% | -4.5% | +33.8% |
2025 Nov 6, 2025 | -59.5% | -13.4% | -1.4% | -8.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STRO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
STRO Max Drawdown
-39.17%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for STRO and SPY.
Company Overview
Sutro Biopharma, Inc.
NASDAQ Global Market
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
- Leadership
- Jane Chung
- IPO Date
- Sep 27, 2018
- Employees
- 269
- Street Address
- 111 Oyster Point Boulevard
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 881 6500
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.0
- Price/Book
- โ
Growth
- Revenue
- +65.2%
- EPS
- +24.0%
- Free Cash Flow
- +8.1%
Profitability
- Gross Margin
- 98.4%
- Operating Margin
- -150.2%
- Net Margin
- -186.5%
- ROE
- 275.3%
- ROIC
- -144.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.